舌下神经刺激治疗唐氏综合征患儿重度阻塞性睡眠呼吸暂停的成本效果
本研究采用成本-效用分析,用马尔可夫模型模拟唐氏综合征合并重度阻塞性睡眠呼吸暂停的儿科队列,比较4岁、13岁(美国食品药品监督管理局当前批准年龄)和18岁植入舌下神经刺激器的成本效果。结果显示各比较组的增量成本效果比均低于每质量调整生命年50000美元的支付意愿阈值,提示舌下神经刺激是具有成本效果的策略,并提示低于13岁植入亦具成本效果。
要点
- 早期(4岁)vs 晚期(13岁)植入的增量成本效果比为每质量调整生命年48892.47美元。
- 早期(4岁)vs 成年(18岁)植入的增量成本效果比为每质量调整生命年43471.15美元。
- 晚期(13岁)vs 成年(18岁)植入的增量成本效果比为每质量调整生命年30959.58美元。
核心结论
- 本研究提示舌下神经刺激是唐氏综合征合并重度阻塞性睡眠呼吸暂停儿科患者具有成本效果的治疗策略。
- 研究结果还提示在低于13岁(美国食品药品监督管理局当前批准年龄)的年龄植入亦具成本效果。
研究设计与样本
- 成本-效用分析,采用马尔可夫模型模拟3个唐氏综合征合并阻塞性睡眠呼吸暂停的儿科队列,从4岁随访至21岁。
- 队列分别在4岁(儿童早期)、13岁(美国食品药品监督管理局当前批准年龄)或18岁(成年期)接受舌下神经刺激植入。
- 模型输入参数来自文献和本机构。
主要发现
- 早期植入组总成本83300.35美元、总质量调整生命年15.79;晚期植入组总成本48319.09美元、总质量调整生命年14.98;成年植入组总成本38721.07美元、总质量调整生命年14.55。
- 早期 vs 晚期植入的增量成本效果比为每质量调整生命年48892.47美元。
- 早期 vs 成年植入的增量成本效果比为每质量调整生命年43471.15美元。
- 晚期 vs 成年植入的增量成本效果比为每质量调整生命年30959.58美元。
- 所有增量成本效果比均低于每质量调整生命年50000美元的支付意愿阈值。
关键数值与推荐
- 增量成本效果比以每质量调整生命年美元数衡量。
- 支付意愿阈值为每质量调整生命年50000美元。
- 阈值分析显示,与晚期植入相比,早期植入在舌下神经刺激植入成本高达62230美元时仍具成本效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the cost-effectiveness of hypoglossal nerve stimulation (HGNS) implantation at an early age in simulated pediatric cohorts with Down Syndrome (DS) and severe obstructive sleep apnea (OSA). STUDY DESIGN: Cost-utility analysis. SETTING: Hypothetical cohort. METHODS: A Markov model simulated 3 pediatric cohorts with DS and OSA beginning at age 4 years until 21 years. Cohorts received HGNS implants in early childhood, late childhood, or adulthood at age 4, 13 (current FDA-approved age), or 18 years, respectively. Input model parameters were obtained from the literature and our institution. Outcomes were measured with an incremental cost-effectiveness ratio (ICER), measured in dollars per quality-adjusted life-year (QALY). Deterministic 1-way sensitivity analyses were conducted to evaluate the effects of parameter uncertainty. RESULTS: Results (total costs; total QALYs) across the time horizon were determined for each cohort: early implantation ($83,300.35; 15.79), late ($48,319.09; 14.98), and adult ($38,721.07; 14.55). ICERs were $48,892.47 per QALY for early vs late implantation, $43,471.15 per QALY for early vs adult implantation, and $30,959.58 per QALY for late vs adult implantation. All ICERs were below a willingness-to-pay threshold of $50,000 per QALY. Varying the discount rate and utility expectedly varied the ICERs and cost-effectiveness. Threshold analysis showed early implantation to be cost-effective for a HGNS implantation cost up to $62,230 compared to late implantation. CONCLUSION: The current study suggests HGNS is a cost-effective treatment strategy for pediatric patients with DS and severe OSA. Our findings also suggest cost-effectiveness at ages younger than 13, the current age of FDA approval.
引用
- Nowlen F, Scheffler P. Cost-Effectiveness of Hypoglossal Nerve Stimulation for Pediatric Severe Obstructive Sleep Apnea in Down Syndrome Patients. Otolaryngol Head Neck Surg. 2024. PMID: 39460614. doi:10.1002/ohn.1030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。